Metamizol Ababor

Metamizole Magnesium, the active ingredient in Metamizol Ababor, is a pyrazolone presented as an oral dosage form for oral use. It is employed to relieve pain, reduce fever, and alleviate visceral spasm in adult patients. GNH USA supplies Metamizol Ababor as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metamizole Magnesium is used within the analgesic, antipyretic and spasmolytic therapeutic class to manage several common conditions.

Pain relief: provides effective analgesia for moderate to severe pain. Fever reduction: lowers elevated body temperature in febrile states. Visceral spasm: relaxes smooth‑muscle spasm of the gastrointestinal tract.

Metamizole Magnesium may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea or vomiting - Dizziness or light‑headedness - Mild hypotension - Transient skin rash - Headache

Serious or Rare Side Effects: - Agranulocytosis (dangerously low white‑blood‑cell count) - Severe cutaneous adverse reactions such as Stevens‑Johnson syndrome - Anaphylactic shock - Hepatic dysfunction - Blood dyscrasias including thrombocytopenia

When prescribing Metamizole Magnesium, clinicians should consider several safety measures.

Assess renal and hepatic function before initiation. Monitor complete blood counts regularly during therapy. Use with caution in patients with known hypersensitivity to pyrazolones. Avoid in individuals with severe infection or bone‑marrow suppression. Adjust dosing in elderly patients or those with comorbidities. Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Metamizole Magnesium can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased risk of bleeding. - Other NSAIDs or COX inhibitors: heightened gastrointestinal toxicity. - Methotrexate: potential for enhanced toxicity.

Moderate Interactions (Monitor Closely): - Antihypertensives: additive hypotensive effect. - Lithium: possible rise in serum lithium levels. - CYP450 inhibitors or inducers: may alter drug metabolism and plasma concentrations.